LTBR

LTBR is a TNF receptor superfamily member that transduces lymphotoxin/LIGHT signals into NF-κB activation to shape immune cell behavior and the tumor microenvironment (PMID:39164890, PMID:23370464). Upon engagement by its LTα1/β2 ligand, LTBR drives the non-canonical NF-κB axis through NIK and RelB, where NIK inhibition abrogates RelB expression and nuclear co-translocation of RelB and p52, promoting tumor cell proliferation (PMID:39164890). Receptor abundance and signaling output are stabilized by physical association with TRAF5, whose loss downregulates LTBR and suppresses LTBR-driven NF-κB signaling (PMID:37366426), while LTBR transcription is directly activated by CREB1 binding at its promoter (PMID:36118831). Through non-canonical NF-κB together with Wnt/β-catenin signaling, LTBR sustains the immunosuppressive M2 phenotype of tumor-associated macrophages (PMID:39429877), and agonistic activation of the receptor on tumor stroma drives high endothelial venule differentiation and tertiary lymphoid structure formation that enhance T cell adhesion and extravasation (PMID:42012453). In cancer cells, LTBR signaling acts alongside IFN sensing as a necessary determinant of CD8+ TIL-mediated, HLA class I-independent cytotoxicity [PMID:bio_10.1101_2025.11.19.689204].

1. 2013 Low

   Established that LTBR directly binds its ligand TNFSF14 (LIGHT) at the protein level, anchoring it as a functional receptor for this ligand.

   Evidence Recombinant soluble TNFSF14 and extracellular LTBR proteins in a confocal binding assay with rabbit splenic T cells

   PMID:23370464

   Open questions at the time

   • Binding shown only in rabbit ortholog without mutagenesis
   • No downstream signaling or affinity quantification
   • Does not address LTα1/β2 ligand binding
2. 2022 Medium

   Identified the upstream transcriptional control of LTBR, showing CREB1 directly activates its promoter and that LTBR in turn modulates NF-κB-dependent epithelial viability.

   Evidence Luciferase reporter and ChIP assays with siRNA knockdown in lung epithelial cells

   PMID:36118831

   Open questions at the time

   • NF-κB branch (canonical vs non-canonical) not resolved
   • Single lab
   • Physiological context of CREB1→LTBR axis unclear
3. 2023 Medium

   Defined TRAF5 as a physical partner that stabilizes LTBR and its NF-κB output, linking receptor levels to a pro-survival, anti-necroptotic program.

   Evidence Reciprocal Co-IP, immunofluorescence, knockdown/overexpression rescue, and xenograft in hepatocellular carcinoma cells

   PMID:37366426

   Open questions at the time

   • Mechanism by which TRAF5 sustains LTBR expression not defined
   • Direct binding interface not mapped
   • Single lab
4. 2024 Medium

   Resolved the core signaling axis, demonstrating that LTα1/β2-LTBR engages NIK→RelB non-canonical NF-κB to drive proliferation.

   Evidence Cholangiocarcinoma cell lines and patient-derived organoids with NIK inhibition, immunoblot, RNA-seq, and in vivo murine models

   PMID:39164890

   Open questions at the time

   • Relative contribution of canonical NF-κB not quantified
   • Single tumor type focus
   • Single lab
5. 2024 Medium

   Established LTBR as a cell-intrinsic driver of tumor-associated macrophage immunosuppression and M2 polarization through non-canonical NF-κB and Wnt/β-catenin.

   Evidence Macrophage-specific LTBR knockout mice with tumor growth, immune phenotyping, and TAM knockdown

   PMID:39429877

   Open questions at the time

   • How Wnt/β-catenin is engaged downstream of LTBR unresolved
   • Ligand source in TME not identified
   • Single lab
6. 2026 Medium

   Showed that agonistic LTBR activation on tumor stroma reprograms the vasculature toward HEV differentiation and TLS formation, enhancing T cell infiltration.

   Evidence FAP-LTBR bispecific agonist in primary endothelial cells, 3D microfluidic models, and multiple murine tumor models with spatial transcriptomics

   PMID:42012453

   Open questions at the time

   • Signaling branch mediating HEV differentiation not dissected
   • Durability of TLS-like aggregates unknown
   • Single lab
7. 2025 Medium

   Implicated LTBR signaling in cancer cells, with IFN sensing, as a necessary co-determinant of HLA-independent CD8+ TIL cytotoxicity, defining a non-classical killing pathway.

   Evidence Whole-genome CRISPR loss-of-function screen and patient-derived TIL-melanoma co-cultures with paired scRNA-seq/scTCR-seq (preprint)

   PMID:bio_10.1101_2025.11.19.689204

   Open questions at the time

   • Preprint, not peer-reviewed
   • Molecular link between LTBR signaling and lysis sensitivity unresolved
   • Ligand source from TIL (LTA/LTB) interaction with cancer-cell LTBR not formally demonstrated

• How LTBR's distinct downstream branches (non-canonical NF-κB, Wnt/β-catenin) are selectively engaged in different cell types and ligand contexts remains unresolved.
• No structural model of ligand-receptor-TRAF assembly in the corpus
• Branch selection determinants unknown
• Integration of IFN and LTBR signals mechanistically undefined